Drug intelligence / Profile preview

Lacticaseibacillus paracasei LP-16

Development stage: Preclinical
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

*Lacticaseibacillus paracasei* LP-16 is a probiotic bacterial strain investigated for its potential anti-obesity and lipid-lowering properties. In preclinical models, LP-16 has demonstrated the ability to significantly reduce body weight, lower blood lipid levels, and alleviate liver oxidative stress. Its mechanism of action involves modulating the gut microbiota composition—specifically by adjusting the Firmicutes/Bacteroidetes ratio—to limit excess energy absorption and promoting the production of beneficial metabolites such as short-chain fatty acids (SCFAs). Additionally, LP-16 appears to regulate gut metabolism by decreasing bile acids and long-chain fatty acids while increasing short peptides and vitamins, thereby improving overall host gut health and addressing metabolic disorders like hyperlipidemia. It also enhances the activity of antioxidant enzymes, including superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px), while reducing pro-inflammatory markers and oxidative stress indicators like malondialdehyde (MDA).

Other names: Lactobacillus paracasei LP-16

Beyond the preview

Go deeper on Lacticaseibacillus paracasei LP-16.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lacticaseibacillus paracasei LP-16.

Explore the full profile